Celldex (CLDX) Stock Forecast & Price Target

Compare

1,246 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CLDX Analyst Ratings

Moderate Buy

9 Buy

1 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Celldex

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CLDX Stock 12 Month Forecast

Average Price Target

$54.90

▲(86.54% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Celldex in the last 3 months. The average price target is $54.90 with a high forecast of $90.00 and a low forecast of $24.00. The average price target represents a 86.54% change from the last price of $29.43.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","34":"$34","53":"$53","72":"$72","91":"$91"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,34,53,72,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30,34.61538461538461,39.230769230769226,43.84615384615385,48.46153846153846,53.07692307692307,57.69230769230769,62.30769230769231,66.92307692307692,71.53846153846153,76.15384615384615,80.76923076923077,85.38461538461539,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30,31.915384615384614,33.83076923076923,35.746153846153845,37.66153846153846,39.57692307692308,41.49230769230769,43.40769230769231,45.323076923076925,47.238461538461536,49.15384615384615,51.06923076923077,52.98461538461538,{"y":54.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30,29.53846153846154,29.076923076923077,28.615384615384617,28.153846153846153,27.692307692307693,27.23076923076923,26.76923076923077,26.307692307692307,25.846153846153847,25.384615384615383,24.923076923076923,24.46153846153846,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.29,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.92,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.16,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.66,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$90.00

Average Price Target$54.90

Lowest Price Target$24.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Edward Nash

Canaccord Genuity

$62

Buy

110.67%

Upside

Reiterated

03/04/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Richard Law CFA

Goldman Sachs

$30→$34

Hold

15.53%

Upside

Reiterated

03/03/26

Celldex price target raised to $34 from $30 at Goldman SachsCelldex price target raised to $34 from $30 at Goldman Sachs

Joseph Pantginis

H.C. Wainwright

$50→$42

Buy

42.71%

Upside

Reiterated

03/02/26

Celldex: Barzolvolimab’s Durable Efficacy in Chronic Urticaria Underpins Buy Rating Ahead of Key Late-Stage Catalysts

Kristen Kluska

Cantor Fitzgerald

$67

Buy

127.66%

Upside

Reiterated

03/01/26

Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)

Sam Slutsky

LifeSci Capital

$61→$70

Buy

137.85%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX) and Recursion Pharmaceuticals (NASDAQ: RXRX)

Alex Thompson CFA

Stifel Nicolaus

$58→$68

Buy

131.06%

Upside

Reiterated

02/26/26

Celldex price target raised to $68 from $58 at StifelCelldex price target raised to $68 from $58 at Stifel

Yatin Suneja

Guggenheim

$90

Buy

205.81%

Upside

Reiterated

02/26/26

Guggenheim Sticks to Their Buy Rating for Celldex (CLDX)

Judah Frommer

Morgan Stanley

$44

Buy

49.51%

Upside

Reiterated

02/26/26

Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

02/25/26

Maintaining Buy on Barzolvolimab: Accelerated Clinical Execution, Best-in-Class Potential, and 2026 Catalyst-Driven Upside

Etzer Darout

Barclays

$24

Sell

-18.45%

Downside

Reiterated

02/25/26

Barclays Reaffirms Their Sell Rating on Celldex (CLDX)

Joseph Catanzaro

Mizuho Securities

$48

Buy

63.10%

Upside

Reiterated

01/09/26

Celldex (CLDX) Gets a Buy from Mizuho Securities

Derek Archila

Wells Fargo

$44→$38

Buy

29.12%

Upside

Reiterated

08/20/25

Celldex price target lowered to $38 from $44 at Wells FargoCelldex price target lowered to $38 from $44 at Wells Fargo

David Lebowitz

Citi

$56→$48

Buy

63.10%

Upside

Reiterated

08/20/25

Celldex price target lowered to $48 from $56 at CitiCelldex price target lowered to $48 from $56 at Citi

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

08/19/25

Celldex's Barzolvolimab: Promising Safety Profile Supports Buy Rating Despite EoE Trial Setback

Trung Huynh

RBC Capital

$44→$38

Buy

29.12%

Upside

Reiterated

05/09/25

Celldex price target lowered to $38 from $44 at UBSCelldex price target lowered to $38 from $44 at UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Edward Nash

Canaccord Genuity

$62

Buy

110.67%

Upside

Reiterated

03/04/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Richard Law CFA

Goldman Sachs

$30→$34

Hold

15.53%

Upside

Reiterated

03/03/26

Celldex price target raised to $34 from $30 at Goldman SachsCelldex price target raised to $34 from $30 at Goldman Sachs

Joseph Pantginis

H.C. Wainwright

$50→$42

Buy

42.71%

Upside

Reiterated

03/02/26

Celldex: Barzolvolimab’s Durable Efficacy in Chronic Urticaria Underpins Buy Rating Ahead of Key Late-Stage Catalysts

Kristen Kluska

Cantor Fitzgerald

$67

Buy

127.66%

Upside

Reiterated

03/01/26

Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)

Sam Slutsky

LifeSci Capital

$61→$70

Buy

137.85%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX) and Recursion Pharmaceuticals (NASDAQ: RXRX)

Alex Thompson CFA

Stifel Nicolaus

$58→$68

Buy

131.06%

Upside

Reiterated

02/26/26

Celldex price target raised to $68 from $58 at StifelCelldex price target raised to $68 from $58 at Stifel

Yatin Suneja

Guggenheim

$90

Buy

205.81%

Upside

Reiterated

02/26/26

Guggenheim Sticks to Their Buy Rating for Celldex (CLDX)

Judah Frommer

Morgan Stanley

$44

Buy

49.51%

Upside

Reiterated

02/26/26

Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

02/25/26

Maintaining Buy on Barzolvolimab: Accelerated Clinical Execution, Best-in-Class Potential, and 2026 Catalyst-Driven Upside

Etzer Darout

Barclays

$24

Sell

-18.45%

Downside

Reiterated

02/25/26

Barclays Reaffirms Their Sell Rating on Celldex (CLDX)

Joseph Catanzaro

Mizuho Securities

$48

Buy

63.10%

Upside

Reiterated

01/09/26

Celldex (CLDX) Gets a Buy from Mizuho Securities

Derek Archila

Wells Fargo

$44→$38

Buy

29.12%

Upside

Reiterated

08/20/25

Celldex price target lowered to $38 from $44 at Wells FargoCelldex price target lowered to $38 from $44 at Wells Fargo

David Lebowitz

Citi

$56→$48

Buy

63.10%

Upside

Reiterated

08/20/25

Celldex price target lowered to $48 from $56 at CitiCelldex price target lowered to $48 from $56 at Citi

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

08/19/25

Celldex's Barzolvolimab: Promising Safety Profile Supports Buy Rating Despite EoE Trial Setback

Trung Huynh

RBC Capital

$44→$38

Buy

29.12%

Upside

Reiterated

05/09/25

Celldex price target lowered to $38 from $44 at UBSCelldex price target lowered to $38 from $44 at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Celldex

3 Months

xxx

Success Rate

15/28 ratings generated profit

Average Return

+10.30%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.57% of your transactions generating a profit, with an average return of +10.30% per trade.

1 Year

Kristen KluskaCantor Fitzgerald

Success Rate

14/21 ratings generated profit

Average Return

+71.91%

reiterated a buy rating 7 days ago

Copying Kristen Kluska's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +71.91% per trade.

2 Years

xxx

Success Rate

11/15 ratings generated profit

Average Return

+17.39%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 73.33% of your transactions generating a profit, with an average return of +17.39% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CLDX Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CLDX has received 9 Buy Ratings, 43 Hold Ratings, and 2 Sell Ratings. CLDX average Analyst price target in the past 3 months is 54.90.

Each month's total comprises the sum of three months' worth of ratings.

CLDX Financial Forecast

CLDX Earnings Forecast

Next quarter’s earnings estimate for CLDX is -$1.20 with a range of -$1.29 to -$1.03. The previous quarter’s EPS was -$1.22. CLDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year CLDX has Performed in-line its overall industry.

CLDX Sales Forecast

Next quarter’s sales forecast for CLDX is $795.00K with a range of $0.00 to $3.00M. The previous quarter’s sales results were $121.00K. CLDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year CLDX has Performed in-line its overall industry.

CLDX Stock Forecast FAQ

What is CLDX’s average 12-month price target, according to analysts?

Based on analyst ratings, Celldex Therapeutics Inc’s 12-month average price target is 54.90.

What is CLDX’s upside potential, based on the analysts’ average price target?

Celldex Therapeutics Inc has 86.54% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CLDX a Buy, Sell or Hold?

Celldex Therapeutics Inc has a consensus rating of Moderate Buy which is based on 9 buy ratings, 1 hold ratings and 1 sell ratings.

What is Celldex Therapeutics Inc’s price target?

The average price target for Celldex Therapeutics Inc is 54.90. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $24.00. The average price target represents 86.54% Increase from the current price of $29.43.

What do analysts say about Celldex Therapeutics Inc?

Celldex Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of CLDX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Celldex (CLDX) Stock Forecast & Price Target

CLDX Analyst Ratings

CLDX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Celldex

CLDX Analyst Recommendation Trends

CLDX Financial Forecast

CLDX Earnings Forecast

CLDX Sales Forecast

CLDX Stock Forecast FAQ

Detailed List of Analyst Forecasts